LLY

951.48

-2.19%↓

JNJ

221.7

-0.2%↓

ABBV

201.07

-0.69%↓

UNH

378.66

+2.77%↑

AZN

182.8

+0.21%↑

LLY

951.48

-2.19%↓

JNJ

221.7

-0.2%↓

ABBV

201.07

-0.69%↓

UNH

378.66

+2.77%↑

AZN

182.8

+0.21%↑

LLY

951.48

-2.19%↓

JNJ

221.7

-0.2%↓

ABBV

201.07

-0.69%↓

UNH

378.66

+2.77%↑

AZN

182.8

+0.21%↑

LLY

951.48

-2.19%↓

JNJ

221.7

-0.2%↓

ABBV

201.07

-0.69%↓

UNH

378.66

+2.77%↑

AZN

182.8

+0.21%↑

LLY

951.48

-2.19%↓

JNJ

221.7

-0.2%↓

ABBV

201.07

-0.69%↓

UNH

378.66

+2.77%↑

AZN

182.8

+0.21%↑

Начало・Списък с акции・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Затворен

СекторЗдравеопазване

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

Максимум

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	-0.05% downside

Настроения в новините

By Acuity

50%

166 / 347 Класиране в Healthcare

Mirati Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

7.05.2026 г., 23:58 ч. UTC

Печалби

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7.05.2026 г., 22:57 ч. UTC

Печалби

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7.05.2026 г., 23:52 ч. UTC

Печалби

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7.05.2026 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7.05.2026 г., 23:39 ч. UTC

Пазарно говорене

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7.05.2026 г., 23:28 ч. UTC

Пазарно говорене

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7.05.2026 г., 23:11 ч. UTC

Печалби

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7.05.2026 г., 23:06 ч. UTC

Печалби

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7.05.2026 г., 23:05 ч. UTC

Печалби

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7.05.2026 г., 23:04 ч. UTC

Печалби

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7.05.2026 г., 23:03 ч. UTC

Печалби

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7.05.2026 г., 23:03 ч. UTC

Печалби

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7.05.2026 г., 23:02 ч. UTC

Печалби

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7.05.2026 г., 23:00 ч. UTC

Пазарно говорене

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7.05.2026 г., 22:45 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

7.05.2026 г., 22:45 ч. UTC

Пазарно говорене

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7.05.2026 г., 22:42 ч. UTC

Печалби

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7.05.2026 г., 22:33 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7.05.2026 г., 22:32 ч. UTC

Печалби

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7.05.2026 г., 22:31 ч. UTC

Печалби

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7.05.2026 г., 22:31 ч. UTC

Печалби

Macquarie: 68% of FY Income From International >MQG.AU

7.05.2026 г., 22:30 ч. UTC

Печалби

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7.05.2026 г., 22:30 ч. UTC

Печалби

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7.05.2026 г., 22:29 ч. UTC

Печалби

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7.05.2026 г., 22:28 ч. UTC

Печалби

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7.05.2026 г., 22:28 ч. UTC

Печалби

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7.05.2026 г., 22:27 ч. UTC

Печалби

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7.05.2026 г., 22:27 ч. UTC

Печалби

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7.05.2026 г., 22:26 ч. UTC

Печалби

Macquarie to End Share Buyback Extended in November>MQG.AU

7.05.2026 г., 22:25 ч. UTC

Печалби

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Сравнение с други в отрасъла

Ценова промяна

Mirati Therapeutics Inc Прогноза

Ценова цел

By TipRanks

-0.05% надолу

12-месечна прогноза

Среден 58.67 USD -0.05%

Висок 59 USD

Нисък 58 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Mirati Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Mirati Therapeutics Inc през последните 3 месеца.

Настроение

By Acuity

166 / 347 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

EBITDA

Оперативна печалба

Относно Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.